ENDRA Life Sciences Reports Improved Financial Performance in Q2 2026

ENDRA Life Sciences Inc. reported its financial results for the second quarter and first half of 2026, revealing a significant shift in its financial performance compared to the previous year. The company recorded a net income of $159,944 for the three months ended June 30, 2026, a notable improvement from a net loss of $1,225,912 during the same period in 2025. For the six months ended June 30, 2026, ENDRA's net loss narrowed to $1,151,489 from $2,262,242 in the prior year. The company did not generate any revenue during either period, maintaining its focus on the development of its TAEUS technology platform for liver fat measurement.

Total operating expenses for the second quarter of 2026 were $1,483,256, up from $1,301,090 in the same quarter of 2025. The increase was primarily driven by a rise in general and administrative expenses, which surged to $1,243,778 from $851,195 year-over-year. This increase was attributed to higher wage-related expenses, including stock compensation, and increased professional fees. Research and development expenses decreased to $233,665 from $381,061, reflecting the completion of initial product development and a shift in focus towards clinical trials and commercialization.

In terms of operational metrics, ENDRA's cash position improved significantly, with total cash and cash equivalents reaching $1,739,943 and restricted cash of $3,800,003 as of June 30, 2026, compared to $762,365 and no restricted cash at the end of 2025. The company’s total assets increased to $7,942,205 from $3,853,797, largely due to the recent capital raise efforts, including a private placement that generated approximately $3.8 million. The company’s total liabilities also rose slightly to $1,632,514 from $1,593,677, primarily due to an increase in warrant liabilities.

Strategically, ENDRA is pursuing a merger with Noble Africa LLC, which is expected to enhance its market position and operational capabilities. The merger agreement, signed on June 25, 2026, is part of a broader strategy to optimize capital preservation and generate returns through a digital asset treasury initiative. The company has also implemented cost-reduction measures, including workforce reductions, to extend its operational runway and focus on product improvements and regulatory strategies. Looking ahead, ENDRA anticipates continued losses as it seeks to commercialize its TAEUS technology, with substantial doubt about its ability to continue as a going concern if the merger does not close or if additional financing is not secured.